Premium
Heterozygous α‐antichymotrypsin and PiZ (α 1 ‐antitrypsin deficiency
Author(s) -
Lindmark B.,
Sveius E.,
Eriksson S.
Publication year - 1990
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1990.tb00483.x
Subject(s) - medicine , asthma , gastroenterology , population , immunology , cohort , allergy , environmental health
In a case‐control study we compared the prevalence of heterozygous deficiency of two closely related anti‐neutrophil protease inhibitors, α 1 ‐antitrypsin and α 1 ‐antichymotrypsin, in 172 consecutive children with asthma. In a cohort study the clinical spectrum and severity were compared. On the basis of family studies 5/172 (2.9%) were classified as heterozygotes for α 1 ‐antichymotrypsin deficiency, a high prevalence compared with that of an unselected adult population (prevalence ratio 4.5 (1.7–11.9), P <0.005). This finding suggests that the carrier state of this rare allele (prevalence 0.64%) may predispose to asthma in children. Among these heterozygous patients the prevalence of positive RAST tests for foodstuffs was significantly increased (prevalence ratio 4.8 (1.7–13.2). P<0.005) and 2/5 manifested food allergy with Quincke oedema. Either the PiMZ or SZ phenotype of α 1 ‐antitrypsin deficiency was found in 12 (7.0%) of the 172 patients, a prevalence similar to that of a normal population (prevalence ratio 1.3 (0.67–2.6), P = 0.44). However, the asthma was more severe among the Z allele carriers, judged by the number of hospital admissions, compared with the non‐Z asthmatic children (mean 2.92 vs. 1.72, P <0.05). The results indicate that heterozygous deficiency of protease inhibitors directed against neutrophil proteases may affect the severity and clinical spectrum of childhood asthma, and to some degree be predisposing.